Anitra Fielding

9.2k total citations · 4 hit papers
57 papers, 5.0k citations indexed

About

Anitra Fielding is a scholar working on Oncology, Genetics and Reproductive Medicine. According to data from OpenAlex, Anitra Fielding has authored 57 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 22 papers in Genetics and 21 papers in Reproductive Medicine. Recurrent topics in Anitra Fielding's work include PARP inhibition in cancer therapy (37 papers), BRCA gene mutations in cancer (22 papers) and Ovarian cancer diagnosis and treatment (21 papers). Anitra Fielding is often cited by papers focused on PARP inhibition in cancer therapy (37 papers), BRCA gene mutations in cancer (22 papers) and Ovarian cancer diagnosis and treatment (21 papers). Anitra Fielding collaborates with scholars based in United Kingdom, United States and Belgium. Anitra Fielding's co-authors include Michael Friedländer, Ronnie Shapira‐Frommer, Jonathan A. Ledermann, Charlie Gourley, Darren Hodgson, Stuart Spencer, Gordon Rustin, Ursula A. Matulonis, Tamar Safra and Clare L. Scott and has published in prestigious journals such as Journal of Clinical Oncology, The EMBO Journal and Cancer.

In The Last Decade

Anitra Fielding

56 papers receiving 4.9k citations

Hit Papers

Olaparib Monotherapy in Patients With Advanced Cancer and... 2014 2026 2018 2022 2014 2014 2023 2016 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
    2014 1.2k citations Ronnie Shapira‐Frommer, Michael Friedländer et al. Journal of Clinical Oncology profile →
  2. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
    2014 1.1k citations Jonathan A. Ledermann, Philipp Harter et al. profile →
  3. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
    2023 432 citations Funda Meric‐Bernstam, Vicky Makker et al. Journal of Clinical Oncology profile →
  4. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
    2016 309 citations Jonathan A. Ledermann, Philipp Harter et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anitra Fielding United Kingdom 24 3.7k 1.9k 1.5k 1.1k 758 57 5.0k
Gillian Mitchell Australia 29 3.5k 0.9× 2.6k 1.4× 1.4k 1.0× 2.5k 2.3× 917 1.2× 113 6.3k
Werner Meier Germany 32 3.3k 0.9× 1.6k 0.9× 3.2k 2.1× 1.0k 1.0× 634 0.8× 166 5.8k
Helen Mackay Canada 41 2.9k 0.8× 2.9k 1.5× 2.2k 1.5× 644 0.6× 1.2k 1.6× 185 7.1k
Stephen A. Cannistra United States 30 1.9k 0.5× 2.0k 1.1× 2.0k 1.3× 491 0.5× 512 0.7× 46 5.1k
Paul DiSilvestro United States 33 2.0k 0.5× 1.3k 0.7× 3.9k 2.6× 715 0.7× 700 0.9× 159 6.4k
Kenneth D. Swenerton Canada 26 2.2k 0.6× 1.2k 0.7× 2.3k 1.6× 473 0.4× 598 0.8× 55 4.6k
M. Kaufmann Germany 41 3.6k 1.0× 1.6k 0.9× 538 0.4× 1.2k 1.1× 828 1.1× 242 6.5k
Amreen Husain United States 32 4.7k 1.3× 1.5k 0.8× 2.5k 1.7× 441 0.4× 1.7k 2.2× 74 8.2k
Heidi J. Gray United States 28 2.7k 0.7× 957 0.5× 1.4k 0.9× 302 0.3× 502 0.7× 93 4.8k
James V. Fiorica United States 31 1.1k 0.3× 971 0.5× 1.3k 0.9× 576 0.5× 462 0.6× 121 4.3k

Countries citing papers authored by Anitra Fielding

Since Specialization
Citations

This map shows the geographic impact of Anitra Fielding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anitra Fielding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anitra Fielding more than expected).

Fields of papers citing papers by Anitra Fielding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anitra Fielding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anitra Fielding. The network helps show where Anitra Fielding may publish in the future.

Co-authorship network of co-authors of Anitra Fielding

This figure shows the co-authorship network connecting the top 25 collaborators of Anitra Fielding. A scholar is included among the top collaborators of Anitra Fielding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anitra Fielding. Anitra Fielding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oaknin, Ana, Jung‐Yun Lee, Vicky Makker, et al.. (2025). Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Advances in Therapy. 42(5). 2015–2018. 2 indexed citations
2.
Oaknin, Ana, Jung‐Yun Lee, Vicky Makker, et al.. (2024). Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Advances in Therapy. 41(11). 4125–4139. 9 indexed citations
3.
4.
Meric‐Bernstam, Funda, Vicky Makker, Ana Oaknin, et al.. (2023). LBA34 Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study. Annals of Oncology. 34. S1273–S1274. 3 indexed citations
5.
6.
Senkus, Elżbieta, Suzette Delaloge, Susan M. Domchek, et al.. (2023). Olaparib efficacy in patients with germline BRCA ‐mutated, HER2 ‐negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial. International Journal of Cancer. 153(4). 803–814. 16 indexed citations
7.
Robson, Mark E., Suzette Delaloge, Susan M. Domchek, et al.. (2023). 200P OlympiAD: Exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC). ESMO Open. 8(1). 101389–101389. 1 indexed citations
8.
Spira, Alexander I., Mark Stewart, Suzanne F. Jones, et al.. (2021). Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group. Clinical Cancer Research. 27(9). 2416–2423. 20 indexed citations
9.
Rolfo, Christian, Judith de Vos‐Geelen, Nicolás Isambert, et al.. (2019). Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment. Clinical Pharmacokinetics. 58(9). 1165–1174. 23 indexed citations
10.
Hodgson, Darren, Brian Dougherty, Zhongwu Lai, et al.. (2018). Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. British Journal of Cancer. 119(11). 1401–1409. 167 indexed citations
11.
Rolfo, Christian, Judith de Vos‐Geelen, Nicolás Isambert, et al.. (2017). PHARMACOKINETICS AND SAFETY OF OLAPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS AND HEPATIC OR RENAL IMPAIRMENT. Clinical Pharmacology & Therapeutics. 101. 1 indexed citations
12.
Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2016). Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. UCL Discovery (University College London). 1 indexed citations
13.
Plummer, Ruth, Helen Swaisland, Karin Leunen, et al.. (2015). Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. 76(4). 723–729. 47 indexed citations
14.
O’Reilly, Eileen M., Mark R. Middleton, Ian Chau, et al.. (2015). Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. Annals of Oncology. 26(4). 804–811. 83 indexed citations
15.
Rolfo, Christian, Helen Swaisland, Karin Leunen, et al.. (2015). Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors. Advances in Therapy. 32(6). 510–522. 40 indexed citations
16.
Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2014). Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer. Obstetrical & Gynecological Survey. 69(10). 594–596. 14 indexed citations
17.
Hoff, Paulo M., Andreas Hochhaus, Bernhard C. Pestalozzi, et al.. (2012). Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). Journal of Clinical Oncology. 30(29). 3596–3603. 112 indexed citations
18.
Mitchell, Claire L., James P.B. O’Connor, Caleb Roberts, et al.. (2010). A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemotherapy and Pharmacology. 68(3). 631–641. 19 indexed citations
19.
Purkins, Lynn, et al.. (2003). Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. British Journal of Clinical Pharmacology. 56(s1). 37–44. 85 indexed citations
20.
Wood, Nolan, Keith Tan, Richard Allan, Anitra Fielding, & D. J. Nichols. (2001). Effect of voriconazole on the pharmacokinetics of omeprazole. 41. 2. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gillian Mitchell Breakdown of academic impact, for papers by Werner Meier Breakdown of academic impact, for papers by Helen Mackay Breakdown of academic impact, for papers by Stephen A. Cannistra Breakdown of academic impact, for papers by Paul DiSilvestro Breakdown of academic impact, for papers by Kenneth D. Swenerton Breakdown of academic impact, for papers by M. Kaufmann Breakdown of academic impact, for papers by Amreen Husain Breakdown of academic impact, for papers by Heidi J. Gray Breakdown of academic impact, for papers by James V. Fiorica
Rankless by CCL
2026